WO2023008793A1 - 단백질 발현을 위한 mrna와 이를 위한 주형 - Google Patents
단백질 발현을 위한 mrna와 이를 위한 주형 Download PDFInfo
- Publication number
- WO2023008793A1 WO2023008793A1 PCT/KR2022/010285 KR2022010285W WO2023008793A1 WO 2023008793 A1 WO2023008793 A1 WO 2023008793A1 KR 2022010285 W KR2022010285 W KR 2022010285W WO 2023008793 A1 WO2023008793 A1 WO 2023008793A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mrna
- region
- transcription vector
- mrna transcription
- nucleotide sequence
- Prior art date
Links
- 108020004999 messenger RNA Proteins 0.000 title claims abstract description 166
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 32
- 102000004169 proteins and genes Human genes 0.000 title abstract description 8
- 238000013518 transcription Methods 0.000 claims abstract description 73
- 230000035897 transcription Effects 0.000 claims abstract description 73
- 239000013598 vector Substances 0.000 claims abstract description 65
- 239000000203 mixture Substances 0.000 claims abstract description 54
- 238000000034 method Methods 0.000 claims abstract description 32
- 230000002163 immunogen Effects 0.000 claims abstract description 20
- 238000000338 in vitro Methods 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 239000000427 antigen Substances 0.000 claims description 58
- 102000036639 antigens Human genes 0.000 claims description 58
- 108091007433 antigens Proteins 0.000 claims description 58
- 239000013612 plasmid Substances 0.000 claims description 45
- 239000002773 nucleotide Substances 0.000 claims description 36
- 125000003729 nucleotide group Chemical group 0.000 claims description 36
- 150000002632 lipids Chemical class 0.000 claims description 26
- 108700026244 Open Reading Frames Proteins 0.000 claims description 22
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 19
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 16
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 12
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 11
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 11
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 11
- 239000002105 nanoparticle Substances 0.000 claims description 9
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 244000052769 pathogen Species 0.000 claims description 6
- 230000001717 pathogenic effect Effects 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 101710137500 T7 RNA polymerase Proteins 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 102000029797 Prion Human genes 0.000 claims description 2
- 108091000054 Prion Proteins 0.000 claims description 2
- 108010065868 RNA polymerase SP6 Proteins 0.000 claims description 2
- 241000726445 Viroids Species 0.000 claims description 2
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 230000002438 mitochondrial effect Effects 0.000 claims description 2
- 244000045947 parasite Species 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 229960005486 vaccine Drugs 0.000 description 35
- 239000005089 Luciferase Substances 0.000 description 23
- 238000010171 animal model Methods 0.000 description 23
- 238000009472 formulation Methods 0.000 description 22
- 210000001744 T-lymphocyte Anatomy 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- 108060001084 Luciferase Proteins 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 230000005847 immunogenicity Effects 0.000 description 13
- 230000028993 immune response Effects 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 102100032912 CD44 antigen Human genes 0.000 description 9
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 9
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 9
- 102100033467 L-selectin Human genes 0.000 description 9
- 229940096437 Protein S Drugs 0.000 description 9
- 101710198474 Spike protein Proteins 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 239000011550 stock solution Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- -1 specifically Proteins 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 108700021021 mRNA Vaccine Proteins 0.000 description 6
- 229940126582 mRNA vaccine Drugs 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
- QGWBEETXHOVFQS-UHFFFAOYSA-N 6-[6-(2-hexyldecanoyloxy)hexyl-(4-hydroxybutyl)amino]hexyl 2-hexyldecanoate Chemical compound CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCO)CCCCCCOC(=O)C(CCCCCC)CCCCCCCC QGWBEETXHOVFQS-UHFFFAOYSA-N 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108091027974 Mature messenger RNA Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- BGNVBNJYBVCBJH-UHFFFAOYSA-N SM-102 Chemical compound OCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCCC(OCCCCCCCCCCC)=O BGNVBNJYBVCBJH-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 2
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- KEQFTVQCIQJIQW-UHFFFAOYSA-N N-Phenyl-2-naphthylamine Chemical compound C=1C=C2C=CC=CC2=CC=1NC1=CC=CC=C1 KEQFTVQCIQJIQW-UHFFFAOYSA-N 0.000 description 2
- 241001112090 Pseudovirus Species 0.000 description 2
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- AGWRKMKSPDCRHI-UHFFFAOYSA-K [[5-(2-amino-7-methyl-6-oxo-1H-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-5-(6-aminopurin-9-yl)-4-methoxyoxolan-2-yl]methoxy-oxidophosphoryl] phosphate Chemical compound COC1C(OP([O-])(=O)OCC2OC(C(O)C2O)N2C=NC3=C2N=C(N)NC3=O)C(COP([O-])(=O)OP([O-])(=O)OP([O-])(=O)OCC2OC(C(O)C2O)N2C=[N+](C)C3=C2N=C(N)NC3=O)OC1N1C=NC2=C1N=CN=C2N AGWRKMKSPDCRHI-UHFFFAOYSA-K 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940021747 therapeutic vaccine Drugs 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- LRFJOIPOPUJUMI-KWXKLSQISA-N 2-[2,2-bis[(9z,12z)-octadeca-9,12-dienyl]-1,3-dioxolan-4-yl]-n,n-dimethylethanamine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC1(CCCCCCCC\C=C/C\C=C/CCCCC)OCC(CCN(C)C)O1 LRFJOIPOPUJUMI-KWXKLSQISA-N 0.000 description 1
- 108700022172 2019-nCoV Vaccine mRNA-1273 Proteins 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001009007 Homo sapiens Hemoglobin subunit alpha Proteins 0.000 description 1
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 229940026207 Moderna COVID-19 vaccine Drugs 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 229940026233 Pfizer-BioNTech COVID-19 vaccine Drugs 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 101710124239 Poly(A) polymerase Proteins 0.000 description 1
- 229930185560 Pseudouridine Natural products 0.000 description 1
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 description 1
- FHHZHGZBHYYWTG-INFSMZHSSA-N [(2r,3s,4r,5r)-5-(2-amino-7-methyl-6-oxo-3h-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[[(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] phosphate Chemical compound N1C(N)=NC(=O)C2=C1[N+]([C@H]1[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=C(C(N=C(N)N4)=O)N=C3)O)O1)O)=CN2C FHHZHGZBHYYWTG-INFSMZHSSA-N 0.000 description 1
- NRLNQCOGCKAESA-KWXKLSQISA-N [(6z,9z,28z,31z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butanoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC\C=C/C\C=C/CCCCC NRLNQCOGCKAESA-KWXKLSQISA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- XVUQPECVOGMPRU-ZPPAUJSGSA-N n,n-dimethyl-1,2-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOC(C)C(N(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC XVUQPECVOGMPRU-ZPPAUJSGSA-N 0.000 description 1
- NFQBIAXADRDUGK-KWXKLSQISA-N n,n-dimethyl-2,3-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC NFQBIAXADRDUGK-KWXKLSQISA-N 0.000 description 1
- GLGLUQVVDHRLQK-WRBBJXAJSA-N n,n-dimethyl-2,3-bis[(z)-octadec-9-enoxy]propan-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/CCCCCCCC GLGLUQVVDHRLQK-WRBBJXAJSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003970 toll like receptor agonist Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Definitions
- Nucleic acid-based treatment and vaccine development technology has shown insufficient efficacy as a therapeutic agent due to insufficient transcription and translation efficiency when applied to a target organism beyond the cell level, which has been pointed out as a limitation in the development of nucleic acid-based therapeutic agents. come. Therefore, increasing the intra/external expression ability of antigenic proteins for the treatment of infectious diseases is one of the essential requirements for the development of pharmaceuticals using artificial nucleic acid molecules.
- securing an mRNA sequence with high stability and translation efficiency has emerged as an essential condition for mRNA-based therapy.
- mRNA “vaccine” refers to medicines used for the prevention and treatment of cancer, infectious diseases, autoimmune diseases, etc. by using a protein encoded by mRNA as an antigen.
- the mRNA vaccine has the advantage of being stable and easy to mass-produce, so it is expected to be widely used as a platform for anti-cancer vaccines and infectious disease vaccines in pandemic situations in the future.
- the mRNA vaccine contains an artificial RNA molecule produced by mimicking the natural mRNA structure as an active ingredient, and its main goal is to strengthen the immune system of an individual by using the RNA molecule.
- the immune activating properties that induce stimulation of adjuvants such as the toll-like receptor agonist (TLR agonist), which naked mRNA has fundamentally, reverse the transcriptional signaling system of mRNA It is known that it inhibits the expression of a sufficient amount of mRNA antigen to exhibit pharmacological activity.
- TLR agonist toll-like receptor agonist
- attempts to manufacture vaccines using modified mRNA from which immunogenicity has been removed or attenuated are actively underway.
- due to the low immunogenicity of mRNA due to the low immunogenicity of mRNA, it also has limitations in inducing effective humoral immunity and/or cellular immune response.
- One aspect is to provide an mRNA transcription vector including a promoter region recognized by RNA polymerase and a gene construct capable of enhancing the expression of a target mRNA antigen.
- Another aspect is to provide a method for preparing an mRNA molecule using an mRNA transcription vector as a template, and an mRNA molecule prepared by the method.
- Another aspect is to provide an immunogenic composition
- an immunogenic composition comprising the mRNA molecule and a pharmaceutically acceptable excipient as active ingredients.
- One aspect is an mRNA transcription vector comprising a promoter region recognized by RNA polymerase and a gene construct operably linked to the promoter region,
- the gene construct comprises a 5'-untranslated region (5'-UTR) region consisting of SEQ ID NO: 1 or a nucleotide sequence having 90% or more sequence identity therewith; an open reading frame (ORF) region comprising a nucleotide sequence encoding a target antigen operably linked to the 5'-UTR region; And a 3'-untranslated region in which a unit sequence consisting of SEQ ID NO: 2 or a nucleotide sequence having 90% or more sequence identity thereto operably linked to the open reading frame region is repeated twice (3'-Untranslated region: 3' -UTR) region, an mRNA transcription vector is provided.
- 5'-UTR 5'-untranslated region consisting of SEQ ID NO: 1 or a nucleotide sequence having 90% or more sequence identity therewith
- ORF open reading frame
- 3'-untranslated region in which a unit sequence consisting of SEQ ID NO: 2 or a nucleotide sequence having 90% or more sequence identity thereto
- nucleotide sequence refers to a polymer material comprising a plurality of nucleotide units, specifically, a polymer in which a plurality of nucleotide units are linked to each other by phosphodiester bonds of a sugar / phosphate backbone
- polynucleotide refers to a polymer material comprising a plurality of nucleotide units, specifically, a polymer in which a plurality of nucleotide units are linked to each other by phosphodiester bonds of a sugar / phosphate backbone
- polynucleotide “nucleic acid”, and “nucleic acid molecule” may be used interchangeably.
- the polynucleotide is a biopolymer essential for life and may be RNA or DNA that encodes genetic information through a unique base sequence.
- the polynucleotide is isolated, artificially synthesized, or non-naturally occurring or engineered, and "non-naturally occurring or engineered” means in nature It means a state created by applying artificial deformation, not a state as it exists.
- the artificial modification may be for improving the expression of the target antigen in cells by mimicking the structure of natural mRNA, specifically, mature mRNA.
- mRNA (Messenger RNA) refers to RNA that is transcribed from a DNA template and transfers genetic information of DNA to ribosomes in the cytoplasm.
- the transcription process in eukaryotic organisms proceeds in the nucleus of a cell and includes the process of processing immature RNA (Premature RNA). Specifically, this process is called post-transcriptional modification, and includes splicing, 5'-capping, polyadenylation, export from the nucleus or mitochondria, etc. includes the process of As a result of this process, mature mRNA containing a nucleotide sequence that can be translated into the amino acid sequence of a specific peptide or protein is produced.
- Premature RNA immature RNA
- the mature mRNA may optionally include a 5'-cap, 5'UTR, open reading frame, 3'UTR, and poly A tail.
- the mRNA may be synthesized according to any of a number of known methods, for example, the mRNA may be synthesized via in vitro transcription (IVT).
- the term "vector” refers to a vector capable of expressing an antigen of interest in a suitable host cell, and refers to a genetic construct comprising regulatory elements operably linked to express a gene insert.
- a vector may include expression control elements such as a promoter, an operator, an initiation codon, a stop codon, a polyadenylation signal, and/or an enhancer, and the promoter of the vector may be constitutive or inducible.
- the vector may be an expression vector capable of stably expressing a target antigen in a host cell.
- the expression vector may be a conventional one used in the art to express foreign proteins in plants, animals, or microorganisms, and the vector may be constructed through various methods known in the art.
- the gene construct sequence described above may be operably linked to a promoter.
- operably linked can refer to the linking of nucleotide sequences on a single nucleic acid fragment such that the function of one is affected by the other.
- the vector may be a vector capable of expressing an mRNA molecule as a target antigen in a host cell, that is, it may refer to an mRNA transcription vector.
- the mRNA transcription vector is composed of a genetic construct in the form of DNA, and may refer to a template DNA for mRNA production.
- the mRNA transcription vector may include a promoter recognized by RNA polymerase, and an mRNA molecule may be generated through a transcription process mediated by the promoter.
- the mRNA transcription vector may be in the form of a plasmid, and the mRNA transcription vector may be a linearized vector, specifically, a linearized plasmid.
- the linearized plasmid can be obtained by contacting the plasmid DNA with a restriction enzyme under suitable conditions such that the restriction enzyme cleaves the plasmid DNA at the recognition site and disrupts the plasmid structure.
- the linearized plasmid includes a free 5' end and a free 3' end, which may be used to perform a subsequent in vitro transcription process.
- known techniques in the art may be applied to elements such as the type of plasmid and a restriction enzyme recognition site without limitation.
- RNA polymerase refers to an enzyme that synthesizes primary transcript RNA from DNA.
- the RNA polymerase may be, for example, T7 RNA polymerase, T3 RNA polymerase, SP6 RNA polymerase, or mitochondrial polymerase (POLRMT).
- promoter region recognized by RNA polymerase may refer to a DNA sequence region that serves as a template capable of generating promoter mRNA recognized by RNA polymerase through the above-described transcription process.
- the promoter region may be recognized by RNA polymerase acting in the cytoplasm, for example, as recognized by T7 RNA polymerase, the nucleotide sequence of SEQ ID NO: 4 or SEQ ID NO: 15 or the above It may consist of a sequence having at least 90% or more sequence identity with the nucleotide sequence.
- identity refers to the overall relationship between polymer molecules, eg, between nucleic acids (eg, DNA molecules and/or RNA molecules) and/or between polypeptides.
- polypeptides are considered “substantially identical” to each other if their amino acid sequences are at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical. do.
- Calculation of percent identity of two nucleic acid or polypeptide sequences can be performed, for example, by aligning the two sequences for optimal comparison purposes (e.g., for optimal alignment, one of the first and second sequences or Gaps may be introduced in both, and non-identical sequences may be disregarded for comparison purposes).
- the length of a sequence aligned for comparison purposes is at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or substantially 100% of the length of the reference sequence.
- the nucleic acid or polypeptide sequences at corresponding positions are then compared. Determination of percent identity between two sequences and comparison of sequences can be accomplished using mathematical algorithms. As is well known to those skilled in the art, amino acid or nucleic acid sequences can be compared using any of a variety of algorithms, including those available in commercial computer programs such as BLASTN for nucleotide sequences and BLASTP, gapped BLAST, and PSIBLAST for amino acid sequences. It can be.
- nucleotide sequence indicates that it is linked or positioned in the direction from the 5' end to the 3' end.
- the gene construct is a technical element for enhancing the expression of mRNA molecules or mRNA antigens, including a 5'-untranslated region; an open reading frame region comprising a nucleotide sequence encoding a target antigen; and a 3'-untranslated region.
- the term "open reading frame” can generally be a sequence of several nucleotide triplets that can be translated into a peptide or protein, interchangeably with the term “protein coding region” can be used
- the open reading frame preferably includes a start codon, that is, a combination of three nucleotide sequences (ATG or AUG) encoding the amino acid methionine, in a subsequent region starting from its 5'-end, and
- the region of the direction may preferably contain a stop codon (e.g., TAA, TAG, TGA, or UAA, UAG, UGA) indicating termination of translation.
- the term “open reading frame region” may refer to a DNA sequence region that serves as a template capable of generating an open reading frame mRNA, ie, a target mRNA antigen, through the above-described transcription process.
- 5'-untranslated region refers to a region located at the 5' end of the open reading frame, specifically, an mRNA region upstream from the initiation codon.
- the term “5'-untranslated region” may refer to a DNA sequence region that serves as a template capable of generating 5'-untranslated region mRNA through the above-described transcription process.
- 3'-untranslated region refers to a region located at the 3' end of the open reading frame, specifically, an mRNA region downstream from a stop codon. refers to The term “3'-untranslated region region” may refer to a DNA sequence region that serves as a template capable of generating 3'-untranslated region mRNA through the above-described transcription process.
- the open reading frame region may include a nucleotide sequence encoding an antigen derived from a pathogen.
- an antigen derived from a pathogen may be selected from the group consisting of virus, bacterium, prion, fungus, protozoon, viroid, and parasite, but is limited thereto it is not going to be
- the open reading frame region may be a nucleotide sequence encoding a viral surface protein or a functional domain thereof, but if it is an mRNA antigen that can infect mammals, including humans, and cause pathological symptoms, it can be expanded without limitation. Applicable.
- the 5'-untranslated region region is a modified sequence derived from human hemoglobin subunit alpha2 (HBA2), and has at least 90% or more sequence identity with the nucleotide sequence of SEQ ID NO: 1 or the nucleotide sequence It may consist of a sequence having.
- HBA2 human hemoglobin subunit alpha2
- the 3'-untranslated region region is a modified sequence derived from human hemoglobin subunit beta (HBA2), having at least 90% sequence identity with the nucleotide sequence of SEQ ID NO: 2 or the nucleotide sequence A unit sequence composed of sequences may be repeated twice.
- the 3'-untranslated region may be composed of nucleotide sequences to which the unit sequences are directly linked or linked by a linker sequence.
- the 3'-untranslated region may consist of the nucleotide sequence of SEQ ID NO: 3 or a sequence having at least 90% sequence identity with the nucleotide sequence.
- the gene construct is a nucleotide sequence operably linked to the 5'-UTR, which is transcribed as a 5' Cap, and/or a poly A tail operably linked to the 3'-UTR region. It may further include a nucleotide sequence to be transcribed.
- 5'Cap refers to a structure located at the 5' terminal region that affects the stability and expression efficiency of a polynucleotide, and is generally modified by a nucleotide, particularly a derivative of guanine nucleotide.
- the 5'cap is m 7 G(5')ppp(5')(2'OMeA)pG, m 7 Gppp, Gppp, m 7 (3'OMeG)(5')ppp(5')(2'OMeA )pG, m 7 (3'OMeG)(5')ppp(5')(2'OMeG)pG, G(5')ppp(5')G, m 7 G(5')ppp(5') G, 3 ⁇ -O-Me-m 7 G(5')ppp(5')G, m 7 G(5')ppp(5')(2'OMeA)pG, or m 7 G(5') It may be any one of ppp(5')(2'OMeA)pU, but a known 5'cap having the same functionality as above may be applied without limitation.
- Poly A tail is located at the 3' end region that affects the expression efficiency by delaying the degradation process of RNA exo-nuclease and extending the stability and in vivo half-life of polynucleotides.
- it can generally be formed by a plurality of adenine nucleotide sequences.
- the poly A tail may consist of 20 to 200 adenines, for example, 20 to 190, 20 to 170, 20 to 150, 20 to 130, 20 to 110, 20 to 90, 20 to 70, 20 to 50, 20 to 30, 30 to 190, 30 to 170, 30 to 150, 30 to 130, 30 to 110, 30 to 90, 30 to 70, or 30 to 50 repetitive adenine nucleotide sequences.
- the poly A tail may be composed of a plurality of units linked by a linker.
- the mRNA transcription vector includes a promoter region and a gene construct consisting of the nucleotide sequence of SEQ ID NO: 4 or SEQ ID NO: 15, and the gene construct consists of the nucleotide sequence of SEQ ID NO: 1 5'- UTR region; an ORF region operably linked to the 5′-UTR region; And it may be a plasmid comprising a 3'-UTR region consisting of the nucleotide sequence of SEQ ID NO: 3.
- the mRNA transcription vector according to one embodiment including a gene construct having a combination of a specific 5'-UTR region and a 3'-UTR region, produces luciferase mRNA with higher efficiency than conventional vectors. was able to manifest.
- the mRNA molecule according to one embodiment prepared by adopting the coronavirus spike protein as the target mRNA antigen induces a high level of immune response when administered to an animal model in the form of a vaccine formulation, including various types of modifications.
- the mRNA transcription vector can be used in the field of manufacturing mRNA molecules and therapeutic agents or vaccines containing the mRNA molecules.
- Another aspect provides a method for producing an mRNA molecule comprising performing in vitro transcription using the mRNA transcription vector as a template, and the mRNA molecule prepared by the method.
- in vitro transcription refers to a process in which a target mRNA molecule is synthesized in a cell-free system (in vitro), and preferably, DNA constituting a transcription vector is a template for mRNA transcript production. , and RNA polymerase can be used to control the transcription process in vitro.
- DNA templates for RNA in in vitro RNA transcription can be obtained by cloning a specific cDNA corresponding to each RNA to be transcribed in vitro and introducing it into a suitable vector for RNA in vitro transcription.
- the performing of the in vitro transcription is performed using an mRNA transcription vector according to an embodiment comprising a gene construct having a combination of the above-described specific 5'-UTR region and 3'-UTR region.
- Other execution conditions or the configuration of the ORF region may be appropriately changed and implemented according to the purpose.
- Another aspect is an immunogenic composition
- an immunogenic composition comprising the mRNA molecule and a pharmaceutically acceptable excipient as active ingredients, a medical use of the mRNA transcription vector or the mRNA molecule prepared by the transcription vector for preparing the immunogenic composition, or a method of stimulating an immune response comprising administering the immunogenic composition to a subject.
- the term "immunogenic composition” refers to an active ingredient effective for inducing a certain level of immunity in a subject against a specific pathogen or disease, or a substance containing an effective amount thereof, and the term “vaccine”, “vaccine” It can be used interchangeably with “agent”, “vaccine composition”.
- the immunogenic composition may be a pharmaceutical composition that induces a decrease in the severity, duration or other symptoms of a disease or symptom associated with infection by a pathogen.
- the immunogenic composition may optionally include pharmaceutically acceptable carriers, diluents, excipients, buffers, salts, surfactants, cryoprotectants, and the like.
- the term "immunogenicity” refers to the ability of a composition to elicit an immune response against a specific pathogen, wherein the immune response is primarily a cellular immune response mediated by cytotoxic T-cells and cytokine-producing T-cells. response, or a humoral immune response mediated primarily by helper T-cells followed by activation of B-cells to produce antibodies.
- the term "pharmaceutically acceptable excipient” may include any substance that maintains the activity of the mRNA molecule when combined/mixed with the mRNA molecule and does not react with the subject's immune system.
- buffer systems such as phosphate buffered saline, surfactants, water, emulsions such as oil/water emulsions and various types of humectants, starch, milk, sugar, certain types of clay, gelatin, stearic acid or salts thereof, magnesium or any standard pharmaceutical excipients such as, but not limited to, calcium stearate, talc, vegetable oils, gums, glycols, or other known excipients.
- the immunogenic composition may be in any form known in the art, for example, in the form of a solution or an injection, but is not limited thereto. In the case of liquid or injection, 10 to 40% of propylene glycol and the like may be contained if necessary. Any diluent or buffer known in the art may be included in the solution or injection.
- the immunogenic composition may be prepared immediately before use by preserving a preparation containing the active ingredient in a container such as a vial and adding a necessary carrier or adjuvant, saline, etc. to the injection before use.
- the mRNA molecule may form a complex with at least one lipid component to form liposomes, lipid nanoparticles, and/or lipoplexes.
- the lipid nanoparticles contain an ionizable cationic lipid as one component, and a helper lipid that encapsulates mRNA or aids in delivery efficiency and stabilization. ), and other ingredients such as stabilizers may also be included.
- the lipid nanoparticle may include cationic and neutral lipids (eg, phospholipids), sterols or steroids (eg, cholesterol), PEG-conjugated lipids, and the like.
- cationic lipid include ALC-0315 ([(4-hydroxybutyl) azanediyl] di (hexane-6,1-diyl) bis (2-hexyldecanoate)), SM-102 (9-Heptadecanyl 8- ⁇ (2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino ⁇ octanoate), N,N-dioleyl-N,N-dimethyIammonium chloride (DODAC), N-(l-(2,3-dioleyloxy )propyl)-N,N,N-trimethylammonium chloride (DOTMA), N-(l-(2,3-
- the lipid nanoparticle is a cationic lipid (in the range of 35 to 60 mol% of total lipids), phospholipids (in the range of 5 to 15 mol% of total lipids), cholesterol (30% of total lipids), such as the type described above. to 50 mol% range), and PEG-conjugated lipids such as DMG-PEG 2000 (0.5 to 2.5 mol% range of total lipids), but is not particularly limited thereto.
- components known in the art may be applied to the lipid nanoparticle, and may include cationic lipids, helper lipids, and PEG-conjugated lipids.
- the cationic lipid is, for example, ALC-0315 and/or SM-102;
- Helper lipids include Distearoylphosphatidylcholine (DSPC) and/or Cholesterol;
- the PEG-conjugated lipid may be ALC-0159, and/or PEG-Dimyristoyl glycerol (PEG-DMG), for example ALC-0315: DSPC: Chol: ALC-0159 (47.5:10:40.8:1.7 mol%) ), but may be a particle made of, but is not limited thereto.
- the lipid compounds disclosed in WO2014/172045A1, WO2020/252589A1, and WO2021/000041A1 may be used as the lipid of the lipid nanoparticle without particular limitation, and PNI123/DSPC/Cholesterol/PEG-DMG (50:10: 38.5 or 37.5: 1.5 or 2.5 mol%), PNI123/DOPE/Cholesterol/PEG-DMG may be used, but is not limited thereto either.
- the term "individual” means a subject in need of treatment or prevention of a disease, and more specifically, a human or non-human primate, mouse, dog, cat, horse, cow, etc. of mammals.
- a target mRNA molecule can be expressed with high efficiency by including a specific gene construct.
- the mRNA molecule prepared by the method induces a high level of immune response in an animal model and can be applied to the treatment or prevention of various infections.
- the mRNA molecule-related technology can be used in the field of manufacturing mRNA molecules and therapeutic agents or vaccines including the mRNA molecules.
- FIG. 1 is a diagram schematically illustrating the structure of an mRNA transcription vector according to an embodiment.
- Figure 2 is a schematic diagram showing the structure of an mRNA transcription vector prepared to compare the intracellular antigen expression level with the mRNA transcription vector according to one embodiment
- Figure 2 A shows pSKBS-Luciferase
- Figure 2 B represents pMod-Luciferase
- C in FIG. 2 represents pBNT-Luciferase.
- FIG. 3 is a result of transfecting HEK 293 cells with a luciferase mRNA molecule prepared using an mRNA transcription vector according to an embodiment, and confirming the luciferase activity accordingly.
- Figure 4 is a result of confirming the antibody titer of IgG in the serum of mice induced by the composition after administering an immunogenic composition containing a coronavirus spike mRNA molecule according to an embodiment to mice.
- Figure 5 is an immunogenic composition comprising a full-length spike mRNA molecule (Spike) or RBD mRNA molecule (RBD) in coronavirus according to an embodiment was administered to a mouse, and then the IgG in the serum of the mouse induced by the composition This is the result of comparing antibody titers.
- Spike spike mRNA molecule
- RBD RBD mRNA molecule
- Figure 6 is a result of comparing antibody titers of IgG in the serum of mice induced by the composition after administering an immunogenic composition comprising a spike mRNA molecule having a modified poly-A tail sequence according to one embodiment to mice. am.
- FIG. 11 shows changes in the ratio of KI-67 + , CD62L low , CD44 high , and CD8 + T cells according to external antigen stimulation in animal models (G1 to G5) to which each vaccine preparation was administered according to an embodiment. This is the result of checking
- FIG. 12 is a result of evaluating immunogenicity to an omicron spike protein antigen over time in animal models (G1 to G5) to which each vaccine formulation according to an embodiment was administered, and FIG. 12 A is the result of confirming the antibody titer level of Omicron RBD IgG1, and B in FIG. 12 is the result of confirming the antibody titer level of Omicron RBD IgG2a.
- FIG. 13 is a result of evaluating immunogenicity to the Wuhan Spike protein antigen over time in animal models (G1 to G5) to which each vaccine formulation according to an embodiment was administered.
- FIG. 13B is the result of confirming the antibody titer level of Wuhan RBD IgG2a
- C of FIG. 13 is the result of confirming the antibody titer level of Wuhan S IgG1
- FIG. 13 D is the result of confirming the antibody titer level of Wuhan S IgG2a.
- VNT50 serum dilution factor
- Example 1 Preparation of mRNA antigen expression system and comparison of expression level of target antigen
- an mRNA transcription vector according to an embodiment was prepared using luciferase mRNA as a target antigen, and the prepared mRNA molecules were transfected into HEK 293 cells, and their expression levels were quantitatively compared.
- the promoter region sequence, 5' UTR region sequence, ORF region sequence, 3' UTR region sequence, and poly A-tail region sequence can be operated sequentially.
- An mRNA transcription vector was prepared using the linked structure as a basic skeleton.
- the T7 promoter and 5'UTR region sequence (SEQ ID NO: 6) were inserted between the KpnI and BamHI recognition sites (GGTACC to GGATCC), and then between the XbaI and HindIII recognition sites of the plasmid ( TCTAGA ⁇ AAGCTT) by inserting 3'UTR and A30LA70 (SEQ ID NO: 7) to construct a pSKBS plasmid (SEQ ID NO: 8).
- the luciferase gene (SEQ ID NO: 9) was inserted between the BamHI and XbaI recognition sites (GGATCC ⁇ TCTAGA) of the plasmid to construct pSKBS-Luciferase plasmid (SEQ ID NO: 10) did
- the genetic information of the main functional structures in the pSKBS-Luciferase plasmid is shown in Table 1 below.
- the pMod-Luciferase plasmid containing 5'UTR and 3'UTR of Moderna (Comparative Example 1), 5'UTR of BioNTech and pBNT-Luciferase plasmids (Comparative Example 2) containing 3'UTR were prepared (2004, NAR, A simple, rapid, high-fidelity and cost effective PCR based two step DNA synthesis method for long gene sequence).
- the pMod-Luciferase plasmid uses the pUC19 plasmid, inserts the T7 promoter and Moderna's 5'UTR region sequence (SEQ ID NO: 11) between the KpnI and BamHI recognition sites (GGTACC to GGATCC), then the plasmid By inserting Moderna's 3'UTR region sequence (SEQ ID NO: 12) between the XbaI and SacII recognition sites (TCTAGA ⁇ CCGCGG), and inserting the luciferase gene between the BamHI and XbaI recognition sites (GGATCC ⁇ TCTAGA) of the plasmid, produced.
- the pBNT-Luciferase plasmid also adopts the recognition site used in the construction of the pMod-Luciferase plasmid, and uses BioNTech's 5'UTR region sequence (SEQ ID NO: 13) and 3'UTR region sequence (SEQ ID NO: 14) in the same way. inserted.
- the structure of the mRNA transcription vector prepared in this example is shown in Figure 2.
- E. coli transformed with the plasmid prepared in Example 1-1 was cultured, the plasmid was isolated therefrom, and the plasmid was linearized using EcoRV restriction enzyme. After recovering the linearized plasmid using PCI ethanol precipitation, it was used in an in vitro transcription (IVT) reaction for mRNA production. To this end, after mixing the linearized plasmid DNA template according to the conditions described in Table 2, the mixture was reacted at 37 °C for 2 hours. Then, after the above reaction was terminated, DNase1 at a concentration of 2 KU/mL was added thereto and reacted at 37° C. for 15 minutes to remove the linearized plasmid.
- IVTT in vitro transcription
- the synthesized mRNA was purified using the MEGAclear Transcription Clean-Up Kit (Thermo Fisher). Then, the HEK293 cell line was transfected with the purified mRNA using LipofectamineTM MessengerMAX (Thermo Fisher). 24 hours after the transfection was performed, the activity of luciferase expressed in the HEK293 cell line was measured using the ONE-GloTM Luciferase Assay System (Promega), and the relative expression level of luciferase was determined through the measured activity. was evaluated. Meanwhile, as a control group, a group (Mock) that did not perform transfection was used.
- FIG. 3 is a result of transfecting HEK 293 cells with a luciferase mRNA molecule prepared using an mRNA transcription vector according to an embodiment, and confirming the luciferase activity accordingly.
- the luciferase mRNA molecule prepared using the mRNA transcription vector according to one embodiment showed a high level of luciferase activity when transfected into a host cell, and through this, by the target mRNA antigen Excellent intracellular expression efficiency was confirmed.
- an mRNA transcription vector according to an embodiment was prepared using corona spike mRNA as the target antigen, and the mRNA molecule produced through this was formulated into a lipid mRNA-LNP (mRNA-lipid Nanoparticle) vaccine formulation, It was administered to an animal model to evaluate the immunogenicity, specifically, the level of antibody formation.
- lipid mRNA-LNP mRNA-lipid Nanoparticle
- An mRNA transcription vector was prepared in a manner similar to Example 1-1. Specifically, in this example, using the pUC19 plasmid and the T7 promoter (SEQ ID NO: 15) in which +1 is A and +2 is G, the promoter and After inserting the 5'UTR region sequence (SEQ ID NO: 16), the 3'UTR and A20 (SEQ ID NO: 17) were inserted between the XbaI and HindIII recognition sites (TCTAGA ⁇ AAGCTT) of the plasmid to obtain pSKBS-AG plasmid (SEQ ID NO: 16). No. 18) was produced.
- the spike gene (SEQ ID NO: 19) of the SARS-CoV2 beta-mutant virus was inserted between the BamHI and XbaI recognition sites (GGATCC ⁇ TCTAGA) of the plasmid, pSKBS-Spike (SA) -AG plasmid (SEQ ID NO: 20) produced.
- mRNA was prepared using the pSKBS-Spike(SA)-AG plasmid prepared above. More specifically, E. coli transformed with the prepared plasmid was cultured, and the plasmid was isolated therefrom, and then the plasmid was linearized using EcoRV restriction enzyme. After the linearized plasmid was recovered using PCI ethanol precipitation, it was used for in vitro transcription reaction for mRNA production. To this end, after mixing the linearized plasmid DNA template according to the conditions described in Table 3, the mixture was reacted at 37 °C for 2 hours. Then, after the reaction was terminated, DNase1 at a concentration of 2 KU/mL was added thereto and reacted at 37° C.
- the materials were mixed under the conditions shown in Table 4 using the Poly(A) Polymerase Tailing Kit (Lucigen), and reacted at 37 °C for 1 hour. Then, the synthesized mRNA was purified by AKTA FPLC (GE Healthcare) using a CIMmultus ® Oligo dT (Sartorius) column.
- the purified mRNA molecule/stock solution of Example 2-1 was formulated as a lipid mixture to prepare mRNA-LNP (Lipid nanoparticle) encapsulated with mRNA in the lipid component.
- mRNA-LNP Lipid nanoparticle
- the mRNA stock solution was diluted to 0.17 mg/mL with Formulation Buffer, GenVoy-ILM (PRECISION NANOSYSTEMS) was diluted 1/2 with ethanol, and each of them was filled into a syringe.
- MWCO 50 kDa centrifugal ultrafiltration unit
- 0.1 mL injection containing 100 ⁇ l of the stock solution containing 5 ⁇ g or 25 ⁇ g of mRNA-LNP prepared in Example 2-2 was injected into an animal model (mouse, BALB/c, female) at week 0, 2 or 3
- Intramuscular administration (IM) was administered twice at weekly intervals.
- serum was separated from specimens collected from animal models before and after administration, and the antibody titer of IgG produced by the vaccine preparation was measured by ELISA (Enzyme-Linked Immunosorbent Assay) using the serum as a sample. Specifically, after coating the surface of a 96-well plate with 1 ⁇ g/mL antigen, it was incubated at 2-8° C. for 18 ⁇ 2 hours.
- Figure 4 is a result of confirming the antibody titer of IgG in the serum of mice induced by the vaccine preparation containing the coronavirus spike mRNA molecule according to an embodiment to mice. As shown in FIG. 4, it was confirmed that an effective level of IgG antibody titer was formed by administering the mRNA-LNP vaccine formulation according to one embodiment, and it was found that the efficacy was enhanced by repeated administration.
- the poly-A tails in this embodiment include a 124 nt-long poly-A tail (A124, SA), a 30 nt-long poly-A and a 70 nt-long poly-A connected by a GCAUAUGACU linker (A30LA70, SAL) was used, and as a modification of the uridine sequence, pseudouridine ( ⁇ ) was applied instead of uridine.
- 5 to 7 are vaccine formulations containing a full-length spike mRNA molecule (Spike) or RBD mRNA molecule (RBD) in coronavirus according to an embodiment, and vaccine formulations including a spike mRNA molecule having a modified poly-A tail sequence, according to an embodiment.
- Spike full-length spike mRNA molecule
- RBD RBD mRNA molecule
- FIGS. 5 to 7 it was confirmed that an effective level of IgG antibody titer was formed even in vaccine formulations including various types of modifications.
- the mRNA transcription vector is the SARS-CoV2 Omicron spike-2P prefusion type gene between the BamHI and XbaI recognition sites (GGATCC to TCTAGA) of the pSKBS-AG plasmid (SEQ ID NO: 18) of Example 2-1 (SEQ ID NO: 21), SARS-CoV2 Omicron spike-6P prefusion type gene (SEQ ID NO: 22), or SARS-CoV2 Wuhan spike-2P prefusion type gene (SEQ ID NO: 23).
- N1-methyl pseudouridine m1 ⁇
- the prepared mRNA was formulated and 0.1 mL of injection containing 100 ⁇ l of stock solution containing 10 ⁇ g of mRNA-LNP was intramuscularly administered to animal models (mouse, BALB/c, female), respectively.
- the prepared mRNA-LNP stock solution was intramuscularly administered (IM) to an animal model (mouse, BALB/c, female). Specifically, it was administered twice at 2-week intervals at week 0 and week 2, and after 1 week of secondary immunization, the spleen was harvested through autopsy, red blood cells were removed from the spleen, and spleen cells were obtained.
- IM intramuscularly administered
- the spleen was harvested through autopsy, red blood cells were removed from the spleen, and spleen cells were obtained.
- CD4 T cells and CD8 T cells responding to the antigen were analyzed by FACS (Fluorescence-activated cell sorting), and the results are shown in FIGS. 8 to 11 .
- FIGS. 10 and 11 show CD103 + , CD62L high , CD44 high , CD4 + T cells and KI-67 according to external antigen stimulation, targeting animal models (G1 to G5) to which each vaccine formulation according to an embodiment was administered.
- FIGS. 10 and 11 are targeting animal models (G1 to G5) administered with each vaccine formulation according to an embodiment, external antigen
- a foreign antigen that is, a spike antigen of SARS-CoV2 antigen mixture, SARS-CoV2 Wuhan or SARS-CoV2 Omicron
- resident memory CD4 T cells CD4 Memory resident T cells
- proliferative memory CD4 T cells CD4 Memory proliferation T cells
- the prepared mRNA-LNP stock solution was intramuscularly administered (IM) to an animal model (mouse, BALB/c, female). It was administered twice at 2-week intervals at 0 and 2 weeks, and serum was separated from blood samples collected before administration and at 2 and 4 weeks after administration. Then, using the separated serum as a sample, the antibody titer of IgG produced by the vaccine preparation was measured through ELISA (Enzyme-Linked Immunosorbent Assay) in the same manner as in Example 2-3. Thereafter, RBD protein and Spike protein of each strain were coated with an antigen to measure Ig antibody titers, and the results are shown in FIGS. 12 and 13 .
- FIG. 12 is a result of evaluating immunogenicity to an omicron spike protein antigen over time in animal models (G1 to G5) to which each vaccine formulation according to an embodiment was administered, and FIG. Immunogenicity to the Wuhan Spike protein antigen was evaluated over time in animal models (G1 to G5) to which each vaccine formulation according to the Example was administered.
- the vaccine formulations prepared according to one embodiment, in view of the antibody formation level were administered with SARS-CoV2 Omicron spike mRNA vaccine formulations over all time points in the G1 group and the G2 group group showed cross-reactivity to the Wuhan spike protein antigen, and it was confirmed that the G5 group administered with the SARS-CoV2 Wuhan spike mRNA vaccine formulation also showed cross-reactivity to the omicron spike protein antigen.
- PBNA Humoral immunoassay
- the prepared mRNA-LNP stock solution was intramuscularly administered (IM) to an animal model (mouse, BALB/c, female). It was administered twice at 2-week intervals, 0 weeks and 2 weeks, and serum was separated from blood samples collected 2 weeks after administration. Thereafter, neutralizing antibody analysis (PBNA) was performed using the separated serum as a sample.
- SARS-CoV2 Wuhan (D614G), VSV pseudotyped virus (REVACC SCIENTIFIC) containing omicron mutant Spike protein and luciferase gene were appropriately diluted. Thereafter, this was mixed with the serial dilution serum sample, treated with the Vero cell line, and infected for 24 hours. Luciferase activity was measured, and the results are shown in FIG. 14 .
- VNT50 serum dilution factor
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (16)
- RNA 중합효소 (RNA polymerase)에 의해 인식되는 프로모터 영역 및 상기 프로모터 영역과 작동 가능하게 연결된, 유전자 컨스트럭트를 포함하는 mRNA 전사 벡터로서,상기 유전자 컨스트럭트는 서열번호 1 또는 이와 90% 이상의 서열 동일성을 갖는 뉴클레오티드 서열로 이루어진 5’-비번역 부위 (5’-Untranslated region: 5’-UTR) 영역;상기 5’-UTR 영역에 작동 가능하게 연결된, 목적 항원을 코딩하는 뉴클레오티드 서열을 포함하는 오픈 리딩 프레임 (Open reading frame: ORF) 영역; 및상기 오픈 리딩 프레임 영역에 작동 가능하게 연결된, 서열번호 2 또는 이와 90% 이상의 서열 동일성을 갖는 뉴클레오티드 서열로 이루어진 단위체 서열이 2회 반복되는 3’-비번역 부위 (3’-Untranslated region: 3’-UTR) 영역을 포함하는 것인, mRNA 전사 벡터.
- 청구항 1에 있어서, 상기 프로모터 영역은 T7 RNA 중합효소, T3 RNA 중합효소, SP6 RNA 중합효소, 또는 미토콘드리아 중합효소(POLRMT) 중 어느 하나의 RNA 중합효소에 의해 인식되는 것인, mRNA 전사 벡터.
- 청구항 1에 있어서, 상기 오픈 리딩 프레임 영역은 병원체로부터 유래되는 항원을 코딩하는 뉴클레오티드 서열을 포함하는 것인, mRNA 전사 벡터.
- 청구항 3에 있어서, 상기 병원체는 바이러스(virus), 박테리아(bacterium), 프리온(prion), 균류(fungus), 원생동물(protozoon), 바이로이드(viroid), 및 기생동물(parasite)로 이루어진 군으로부터 선택되는 것인, mRNA 전사 벡터.
- 청구항 1에 있어서, 상기 3’-UTR 영역은 상기 단위체 서열이 직접 연결되거나, 링커 서열에 의해 연결되어 있는 뉴클레오티드 서열로 이루어지는 것인, mRNA 전사 벡터.
- 청구항 1에 있어서, 상기 유전자 컨스트럭트는 상기 5’-UTR에 작동 가능하게 연결된, 5' 캡 (5' Cap)으로 전사되는 뉴클레오티드 서열을 추가로 포함하는 것인, mRNA 전사 벡터.
- 청구항 1에 있어서, 상기 유전자 컨스트럭트는 상기 3’-UTR 영역에 작동 가능하게 연결된, 폴리 A 테일로 전사되는 뉴클레오티드 서열을 추가로 포함하는 것인, mRNA 전사 벡터.
- 청구항 7에 있어서, 상기 폴리 A 테일은 20 내지 200개의 아데닌으로 이루어진 것인, mRNA 전사 벡터.
- 청구항 1에 있어서, 상기 mRNA 전사 벡터는 플라스미드인 것인, mRNA 전사 벡터.
- 청구항 1에 있어서, 상기 mRNA 전사 벡터는 선형화된 것인, mRNA 전사 벡터.
- 청구항 1에 있어서, 상기 mRNA 전사 벡터는 서열번호 4 또는 서열번호 15의 뉴클레오티드 서열로 이루어진 프로모터 영역 및 유전자 컨스트럭트를 포함하며,상기 유전자 컨스트럭트는 서열번호 1의 뉴클레오티드 서열로 이루어진 5’-UTR 영역; 상기 5’-UTR 영역에 작동 가능하게 연결된, ORF 영역; 및 서열번호 3의 뉴클레오티드 서열로 이루어진 3’-UTR 영역을 포함하는 것인, mRNA 전사 벡터.
- 청구항 1의 mRNA 전사 벡터를 주형으로 하여 시험관내 전사(in vitro transcription)를 수행하는 단계를 포함하는, mRNA 분자를 제조하는 방법.
- 청구항 12의 방법에 의해 제조된 mRNA 분자.
- 청구항 13의 mRNA 분자 및 약학적으로 허용가능한 부형제를 유효 성분으로 포함하는, 면역원성 조성물.
- 청구항 14에 있어서, 상기 mRNA 분자는 적어도 하나 이상의 지질 성분과 복합체를 형성하여, 리포솜(liposomes), 지질 나노입자(lipid nanoparticles) 및/또는 리포플렉스(lipoplexes)를 형성하는 것인, 면역원성 조성물.
- 청구항 14에 있어서, 상기 면역원성 조성물은 근육 또는 피하 투여되는 것인, 면역원성 조성물.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22849769.9A EP4379055A1 (en) | 2021-07-27 | 2022-07-14 | Mrna for protein expression and template therefor |
CN202280046529.XA CN117940568A (zh) | 2021-07-27 | 2022-07-14 | 一种用于蛋白质表达的mRNA及其模板 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20210098684 | 2021-07-27 | ||
KR10-2021-0098684 | 2021-07-27 | ||
KR10-2022-0062306 | 2022-05-20 | ||
KR20220062306 | 2022-05-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023008793A1 true WO2023008793A1 (ko) | 2023-02-02 |
Family
ID=85087146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/010285 WO2023008793A1 (ko) | 2021-07-27 | 2022-07-14 | 단백질 발현을 위한 mrna와 이를 위한 주형 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4379055A1 (ko) |
KR (1) | KR20230017730A (ko) |
WO (1) | WO2023008793A1 (ko) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014172045A1 (en) | 2013-03-15 | 2014-10-23 | The University Of British Columbia | Lipid nanoparticles for transfection and related methods |
US20170202979A1 (en) * | 2014-07-17 | 2017-07-20 | Modernatx, Inc. | Terminal modifications of polynucleotides |
KR20180038564A (ko) * | 2015-08-28 | 2018-04-16 | 큐어백 아게 | 신규 인공 핵산 분자 |
KR20180057647A (ko) * | 2015-10-07 | 2018-05-30 | 비온테크 알엔에이 파마슈티컬스 게엠베하 | Rna의 안정화를 위한 3' utr 서열 |
US20190002906A1 (en) * | 2017-05-31 | 2019-01-03 | Arcturus Therapeutics, Inc. | Synthesis and structure of high potency rna therapeutics |
US20190111074A1 (en) * | 2016-05-27 | 2019-04-18 | Transcriptx, Inc. | Treatment of primary ciliary dyskinesia with synthetic messenger rna |
WO2020252589A1 (en) | 2019-06-20 | 2020-12-24 | Precision Nanosystems Inc. | Ionizable lipids for nucleic acid delivery |
WO2021000041A1 (en) | 2019-06-29 | 2021-01-07 | Precision Nanosystems Inc. | Ionizable lipids for nucleic acid delivery |
KR20210098684A (ko) | 2020-02-03 | 2021-08-11 | 한국전자통신연구원 | 초고주파 및 초광대역을 지원하는 통신 시스템에서 스케줄링을 위한 방법 및 장치 |
KR20220017377A (ko) | 2020-08-04 | 2022-02-11 | 성균관대학교산학협력단 | 동력학적 제어가 가능한 아주번트를 포함하는 mRNA 백신 |
KR20220062306A (ko) | 2019-09-13 | 2022-05-16 | 코르보 유에스, 인크. | 기울어진 c축 배향을 가진 압전 벌크 층 및 그 제조 방법 |
-
2022
- 2022-07-14 WO PCT/KR2022/010285 patent/WO2023008793A1/ko active Application Filing
- 2022-07-14 KR KR1020220086988A patent/KR20230017730A/ko unknown
- 2022-07-14 EP EP22849769.9A patent/EP4379055A1/en active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014172045A1 (en) | 2013-03-15 | 2014-10-23 | The University Of British Columbia | Lipid nanoparticles for transfection and related methods |
US20170202979A1 (en) * | 2014-07-17 | 2017-07-20 | Modernatx, Inc. | Terminal modifications of polynucleotides |
KR20180038564A (ko) * | 2015-08-28 | 2018-04-16 | 큐어백 아게 | 신규 인공 핵산 분자 |
KR20180057647A (ko) * | 2015-10-07 | 2018-05-30 | 비온테크 알엔에이 파마슈티컬스 게엠베하 | Rna의 안정화를 위한 3' utr 서열 |
US20190111074A1 (en) * | 2016-05-27 | 2019-04-18 | Transcriptx, Inc. | Treatment of primary ciliary dyskinesia with synthetic messenger rna |
US20190002906A1 (en) * | 2017-05-31 | 2019-01-03 | Arcturus Therapeutics, Inc. | Synthesis and structure of high potency rna therapeutics |
WO2020252589A1 (en) | 2019-06-20 | 2020-12-24 | Precision Nanosystems Inc. | Ionizable lipids for nucleic acid delivery |
WO2021000041A1 (en) | 2019-06-29 | 2021-01-07 | Precision Nanosystems Inc. | Ionizable lipids for nucleic acid delivery |
KR20220062306A (ko) | 2019-09-13 | 2022-05-16 | 코르보 유에스, 인크. | 기울어진 c축 배향을 가진 압전 벌크 층 및 그 제조 방법 |
KR20210098684A (ko) | 2020-02-03 | 2021-08-11 | 한국전자통신연구원 | 초고주파 및 초광대역을 지원하는 통신 시스템에서 스케줄링을 위한 방법 및 장치 |
KR20220017377A (ko) | 2020-08-04 | 2022-02-11 | 성균관대학교산학협력단 | 동력학적 제어가 가능한 아주번트를 포함하는 mRNA 백신 |
Non-Patent Citations (1)
Title |
---|
no. 1224606-06-7 |
Also Published As
Publication number | Publication date |
---|---|
KR20230017730A (ko) | 2023-02-06 |
EP4379055A1 (en) | 2024-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU722138B2 (en) | Recombinant vector containing a sequence of a lipoprotein gene for the expression of nucleotide sequences | |
CN114081943B (zh) | 一种水痘-带状疱疹mRNA疫苗组合物及其制备方法和应用 | |
KR101866301B1 (ko) | 하나 이상의 cxxc 모티프를 포함하는 폴리펩티드 및 이종 항원을 포함하는 약학 조성물 및 이의 용도 | |
KR20010032425A (ko) | Ltb 보강제를 갖는 백신 | |
TW202216739A (zh) | 一種mRNA及包含其的新型冠狀病毒mRNA疫苗 | |
EP4047013A1 (en) | Carrier protein with site-directed mutation and use thereof in preparation of vaccine | |
US11931410B1 (en) | SARS-CoV-2 mRNA vaccine and preparation method and use thereof | |
WO2021262672A1 (en) | Sars-cov-2 rbd constructs | |
WO2023051701A1 (zh) | 抗SARS-CoV-2感染的mRNA、蛋白以及抗SARS-CoV-2感染的疫苗 | |
JP2872254B2 (ja) | インフルエンザ菌用ワクチンおよび診断法 | |
TW202222821A (zh) | 用於預防及/或治療covid-19之組合物及方法 | |
McAtee et al. | Expression, purification, immunogenicity and protective efficacy of a recombinant nucleoside hydrolase from Leishmania donovani, a vaccine candidate for preventing cutaneous leishmaniasis | |
CN115819616A (zh) | 一种基因重组vzv融合蛋白及其制备方法和应用 | |
US20230174588A1 (en) | A vaccine against sars-cov-2 and preparation thereof | |
WO2023008793A1 (ko) | 단백질 발현을 위한 mrna와 이를 위한 주형 | |
JP2003515342A (ja) | シュードモナス・エルジノサ抗原 | |
WO2023236468A1 (zh) | 一种冠状病毒s蛋白变体及其应用 | |
EP0320866A2 (en) | A protective immunodominant epitope included in the S1 subunit of pertussis toxin | |
WO2022047176A2 (en) | Single-chain coronavirus viral membrane protein complexes | |
CN117940568A (zh) | 一种用于蛋白质表达的mRNA及其模板 | |
WO2023195566A1 (ko) | 사스-코로나바이러스 2 감염증에 대한 rna 백신 | |
WO2024055273A1 (zh) | 一种狂犬病mRNA疫苗、其制备及应用 | |
CA2090005C (en) | Cross-reactive influenza a immunization | |
WO2024125597A1 (en) | Compositions and methods for infectious diseases | |
CN117205309A (zh) | 一种流感免疫原组合物和制备方法及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22849769 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280046529.X Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2024503485 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022849769 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022849769 Country of ref document: EP Effective date: 20240227 |